1. The Unaudited Standalone Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30, 2025 together with Statement of Assets and Liabilities ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fabino Enterprises Ltd (formerly Fabino Life Sciences) reported its H1 FY26 (April–September 2025) results, approved at the board meeting on November 13, 2025. On a standalone basis, revenue from operations collapsed about 84% year-on-year to just Rs. 67.99 lakhs (from Rs. 425.12 lakhs in H1 FY25), and the company slipped into a net loss of Rs. 24.87 lakhs versus a Rs. 4.65 lakh profit a year ago, dragging EPS to a negative Rs. 1.18. Consolidated results, which include subsidiary Upender Metaplast Pvt Ltd, showed revenue growing roughly 56% year-on-year to Rs. 663.34 lakhs, but the group still posted a consolidated net loss of Rs. 18.59 lakhs (vs Rs. 2.79 lakh profit), with EPS at negative Rs. 0.89. Reserves on a standalone basis fell to Rs. 194.03 lakhs from Rs. 218.90 lakhs, and the balance sheet shrank from Rs. 1,300.64 lakhs to Rs. 967.55 lakhs, with cash of just Rs. 19.64 lakhs. The auditor (DGMS & Co.) issued an unqualified limited review report with no qualifications, qualifications-related items, or emphasis of matter.
The 84% standalone revenue crash and return to losses is a clear negative signal for the core business, while the consolidated picture is mixed — strong top-line growth from the subsidiary is being eaten up by costs, leaving the group unprofitable. The stock is on the BSE SME platform (small-cap, higher risk), and with reserves eroding and cash buffer at under Rs. 20 lakhs, near-term pressure on profitability and liquidity is worth watching closely.